Chronic Hepatitis

Top Story

Merck announces Zepatier coverage by Ontario, British Columbia

February 24, 2017

Ontario will become the first Canadian province to reimburse for Zepatier in the treatment of chronic hepatitis C, effective Feb. 28, 2017, followed by British Columbia on Mar. 21, 2017, according to a press release from Merck.

Zepatier (elbasvir/grazoprevir, Merck Canada) is a once-daily pill to be taken for 12 weeks. It is indicated in the treatment of chronic HCV genotypes 1, 3 or 4 infections in adult patients and has no ribavirin regimen for most patients.

Meeting News

ACIP recommends single-dose revaccination for infants born to HBV-infected mothers

February 22, 2017
The Advisory Committee on Immunization Practices voted today in favor of single-dose alternative to 3-dose revaccination for infants born to hepatitis B surface…
In the Journals

ACIP updates adult immunization schedule for influenza, HPV, HBV, meningococcal vaccines

February 6, 2017
The Advisory Committee on Immunization Practices released its 2017 Recommended Immunization Schedule for adults aged 19 years and older, including new or revised…
Perspective

Report raises questions about long-term effects of DAAs for HCV

January 25, 2017
Researchers raised questions about the long-term safety of direct-acting antivirals for hepatitis C virus infection after an analysis of FDA data uncovered more than 500…
CME

HCV Updates and Case Challenges for the Rapidly Changing Landscape

This activity is supported by an educational grant from Merck & Co., Inc.

In the past few years, significant progress has been made in the treatment of chronic hepatitis C virus (HCV). Highly…
More »
GI Bookshelf

Question 37: Which Asymptomatic Patients With Cirrhosis Should Undergo An Upper Endoscopy To Determine Whether They Have Esophageal Varices?

From Curbside Consultation of the Liver: 49 Clinical Questions
More »
Featured
Video
Meeting News Coverage

Sofosbuvir/ledipasvir regimen produced high SVR rates in patients with decompensated cirrhosis

November 14, 2014
More »

Merck announces Zepatier coverage by Ontario, British Columbia

February 24, 2017
Ontario will become the first Canadian province to reimburse for Zepatier in the treatment of chronic hepatitis C, effective Feb. 28, 2017, followed…

Meeting News

ACIP recommends single-dose revaccination for infants born to HBV-infected mothers

February 22, 2017
The Advisory Committee on Immunization Practices voted today in favor of single-dose alternative to 3-dose revaccination for infants born to…

In the Journals

ACIP updates adult immunization schedule for influenza, HPV, HBV, meningococcal vaccines

February 6, 2017
The Advisory Committee on Immunization Practices released its 2017 Recommended Immunization Schedule for adults aged 19 years and older, including…

Perspective

Report raises questions about long-term effects of DAAs for HCV

January 25, 2017
Researchers raised questions about the long-term safety of direct-acting antivirals for hepatitis C virus infection after an analysis of FDA data…

Georgia State, GeoVax partner to develop HBV vaccine

January 19, 2017
The Georgia State University Research Foundation announced it will partner with GeoVax Labs in the development of a therapeutic vaccine for chronic…

Quest Diagnostics launches test for monitoring response to HBV therapies

January 18, 2017
Quest Diagnostics has launched a new hepatitis B virus surface antigen quantitative testing service for evaluating response to treatment. HBsAg…

European Commission approves Vemlidy for chronic HBV

January 12, 2017
The European Commission issued marketing authorization for Vemlidy, a once-daily oral treatment for chronic hepatitis B virus infection in adults and…

In the Journals Plus

Short-term cost of interferon-free therapies for all HCV patients high yet cost-effective

January 9, 2017
A recent cost-effectiveness analysis evaluating the value of interferon-free therapies for the treatment of hepatitis C virus infection genotype 1…

Special Issue Article

Viral Hepatitis in Children: A Through E

Pediatric Annals, December 2016, Volume 45 Issue 12
Hepatitis is defined as inflammation of the liver. This inflammation can be acute and self-limited, chronic (leading to cirrhosis and an increased…

Meeting News

IBD patients on dual therapy undergo more HBV, TB screenings

December 13, 2016
ORLANDO — More patients with inflammatory bowel disease who receive dual biologic or immunosuppressive therapy undergo screening for hepatitis…

More Headlines »
Advertisement
Advertisement